Cover Image

Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice

Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated - with many anticancer therapies and can negatively impact patients' quality of life and potentially - limit the effectiveness of chemotherapy. Currently, CINV can be prevented in most patients with - guideline...

Full description

Saved in:
Bibliographic Details
Main Authors: Aapro, Matti S. (Author) , Jordan, Karin (Author) , Scotté, Florian (Author) , Celio, Luigi (Author) , Karthaus, Meinolf (Author) , Roeland, Eric (Author)
Format: Article (Journal)
Language:English
Published: 18 July, 2022
In: Current cancer drug targets
Year: 2022, Volume: 22, Issue: 10, Pages: 806-824
ISSN:1873-5576
DOI:10.2174/1568009622666220513094352
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.2174/1568009622666220513094352
Verlag, lizenzpflichtig, Volltext: https://www.eurekaselect.com/article/123486
Get full text
Author Notes:Matti Aapro, Karin Jordan, Florian Scotté, Luigi Celio, Meinolf Karthaus and Eric Roeland
Description
Summary:Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated - with many anticancer therapies and can negatively impact patients' quality of life and potentially - limit the effectiveness of chemotherapy. Currently, CINV can be prevented in most patients with - guideline-recommended antiemetic regimens. However, clinicians do not always follow guidelines, - and patients often face difficulties adhering to their prescribed treatments. Therefore, approaches to - increase guideline adherence need to be implemented.
Item Description:Gesehen am 10.01.2023
Physical Description:Online Resource
ISSN:1873-5576
DOI:10.2174/1568009622666220513094352

Similar Items